- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06037265
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
September 7, 2023 updated by: PAVmed Inc.
First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System to Evaluate Safety and Performance
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access.
The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open label, single arm, non-randomized, multicentric first in human clinical trial of the PortIO device for intraosseous infusion of fluids and/or medications for up to 60 days in subjects that meet the inclusion criteria.
Both hospitalized patients as well as outpatients can be screened and, if appropriate, can be consented and enrolled into the study.
They will have the PortIO device implanted by a qualified physician and then undergo prescribed infusions as needed and determined by the treating physician over either a 7-day or a 60-day period.
The device will then be removed after the 7 days or 60 days of use and the subject followed up at 30 days after explant.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia
- Cediul
-
Barranquilla, Atlantico, Colombia
- Sabbag Radiologos
-
-
Bogota
-
Bogotá, Bogota, Colombia
- Cirulaser Andes
-
-
Valle De Cauca
-
Cali, Valle De Cauca, Colombia
- Centro Médico Imbanaco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Subjects must meet the following criteria are eligible for participation in the study:
- Subject is > 22 years old
- Subject has grade 3 or higher CKD and is receiving or may receive renal replacement therapy with hemodialysis OR has poor/difficult vascular access.
- Subject does NOT need urgent or emergent vascular access;
- Subject, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures
- Subject is willing and able to complete follow-up requirement
Exclusion Criteria:
Subjects must be EXCLUDED from participation in this study if ANY of the following criteria are met:
- Fracture (within 6 months), bone tumor, or structural bone abnormality (such as osteogenesis imperfect, avascular necrosis, and severe osteoporosis) of the target bone
- Excessive overlying soft tissue, nerves, arteries, tendons or absence of anatomic landmarks at the target site
- Previous orthopedic procedure at or near the insertion site (e.g. artificial joint, rigid fixation hardware)
- IO access or attempted IO access in the target bone within 7 days
- Known or suspected allergy to any device component or materials contained in the device
- Local tissue factors preventing proper device stabilization and / or access including local infection, fragile tissue and absence of adequate or excessive overlying soft tissue.
- Subject with known unstable cardiac disease (recent MI within 30 days, cardiac surgery within 6 months, unstable angina, severe aortic stenosis/regurgitation, severe congestive heart failure, severe mitral stenosis/regurgitation), uncontrolled diabetes (blood glucose >240 mg/dl) or subjects on immunosuppressive medications (e.g. organ transplant patients)
- Subjects who are anticipated to receive infusion of blood or blood products, chemotherapeutic agents, hypertonic solutions, caustic agents or any agents known to harm bone marrow or cause bone marrow suppression such as azathioprine, procainamide, sulfasalazine via the test device.
- Insertion into the humerus on the same side as a previous mastectomy
- Known allergy to contrast media or local anesthetics (e.g. lidocaine, bupivacaine)
- Subjects with known bleeding disorders including thrombocytopenia, thrombasthenia, hemophilia or Von Willebrand's disease.
- Subjects with a history of hypercoagulable disorders such as protein S or C deficiency, Factor 5 Leiden resistance, Antithrombin III deficiency, Antiphospholipid antibody syndrome, Heparin Induced Thrombocytopenia etc.
- Subjects who are anticipated to need power injections via the test device for CT scan or angiography
- Subject has other medical, social or psychological problem that in the opinion of the investigator precludes them from fully participating
- Women who are pregnant, women who are attempting to become pregnant, as well as women who are breast feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Total Sample Size
The total sample size will be up to 40 subjects that complete the full intended implant durations of either 7 days (n=up to 10) or60 days (n=up to 30).
Group 1 patients will be enrolled first and at least 5 patients will complete the 7-day implant duration before Group 2 patients begin enrollment.
Group 1 and Group 2 subjects can be screened in parallel.
Group 2 enrollment will start immediately after at least 5 subjects in Group 1 have successfully completed the 7-day implantation period.
Study subjects will have the PortIO device implanted by a qualified physician (Table 5) and then undergo prescribed, standard of care infusion regimen as determined by their treating physician over either the 7-day or the 60-day period.
After the intended implant duration and use during the implant period, the device will then be removed and the subject will be followed for safety at 30 days after explant.
|
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access.
The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Performance
Time Frame: Entire duration of Study an average of 2 years
|
Incidence of successful implant in the target anatomic location; Patency through the implant duration, with final patency assessment performed immediately prior to device explant; Incidence of successful device explant
|
Entire duration of Study an average of 2 years
|
Primary Safety
Time Frame: Entire duration of Study and average of 2 years
|
Incidence of serious device-related adverse events
|
Entire duration of Study and average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Endpoint
Time Frame: Entire duration of Study an average of 2 years
|
Incidence of all device-related adverse events, whether serious or non-serious
|
Entire duration of Study an average of 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Gisella Lopez, Lucid Diagnostics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2022
Primary Completion (Estimated)
November 1, 2023
Study Completion (Estimated)
November 1, 2023
Study Registration Dates
First Submitted
August 29, 2023
First Submitted That Met QC Criteria
September 7, 2023
First Posted (Actual)
September 14, 2023
Study Record Updates
Last Update Posted (Actual)
September 14, 2023
Last Update Submitted That Met QC Criteria
September 7, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-0164
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 5
-
Heinrich-Heine University, DuesseldorfRecruitingVaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With TransplantGermany
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
Zydus Lifesciences LimitedCompletedAnemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4India
-
National University, SingaporeUnknownChronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4Singapore
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
-
liberDi Ltd.RecruitingChronic Kidney Disease Stage 5Israel
-
ShireCompletedChronic Kidney Disease, Stage 5United States, Germany, Puerto Rico, United Kingdom
-
National University of SingaporeUnknownStage 5 Chronic Kidney DiseaseSingapore
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States
Clinical Trials on PAVmed PortIO™ Intraosseous Infusion System
-
M.D. Anderson Cancer CenterTriSalus Life SciencesRecruiting
-
CorFlow Therapeutics AGRecruitingSTEMI - ST Elevation Myocardial Infarction | Microvascular ObstructionSwitzerland, Lithuania
-
Nantes University HospitalCompletedComparison of Osteocentral Versus Locoregional Anesthesia in Case of Mandibular Molar Pulpitis (COQ)Endodontic InflammationFrance
-
MedtronicNeuroCompletedChronic Pain | Pain, Back | Chronic Non-malignant Pain | Pain, LegUnited States
-
Kinderkrankenhaus auf der BultCompleted
-
Medtronic Corporate Technologies and New VenturesCompleted
-
Ohio State University Comprehensive Cancer CenterWithdrawnStage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma
-
AmgenCompletedMigraineUnited States, Germany, Denmark, Canada, Finland, Sweden, Norway
-
St. Jude Children's Research HospitalTerminatedAcute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myelogenous Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)United States
-
St. Jude Children's Research HospitalRecruitingAcute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myeloid Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)United States